Symptomatic and asymptomatic visual loss in patients taking vigabatrin

Hossein Danesvar, Lyne Racette, Stuart G. Coupland, Peter J. Kertes, Alan Guberman, David Zackon

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

Purpose: To investigate the clinical, perimetric, and electrophysiologic findings in patients with visual field loss on long-term treatment with the antiepileptic medication vigabatrin. Design: Consecutive observational case series. Participants: Forty-one consecutive subjects taking vigabatrin referred for screening ophthalmologic assessment were studied. Twelve subjects with evidence of peripheral visual field constriction are presented. Methods: Twelve subjects with evidence of peripheral visual field constriction on 60-4 perimetry underwent central 30-2 and blue-on-yellow (B/Y) perimetry, as well as electroretinography (ERG), electro-oculography (EOG), and visual-evoked potential (VEP) testing. Main Outcome Measures: Visual acuity; fundus abnormalities; visual field loss; and ERG, EOG, or VEP abnormalities were the main outcome measures. Results: Eight of the 12 subjects with constricted visual fields were asymptomatic. The central 30-2 perimetry demonstrated bilateral visual field constriction in 9 of 12 patients and the B/Y perimetry in 8 of 9 patients tested. Of the ten patients tested electrophysiologically, four had abnormal ERGs, five had abnormal EOGs, and three had delayed VEPs. Conclusions: The incidence of visual field constriction in patients taking vigabatrin may be higher, and asymptomatic visual field loss more common, than reported previously. The authors postulate a possible Muller cell dysfunction in the peripheral retina. Patients taking vigabatrin should have regular peripheral visual field examinations.

Original languageEnglish (US)
Pages (from-to)1792-1798
Number of pages7
JournalOphthalmology
Volume106
Issue number9
StatePublished - Sep 1 1999
Externally publishedYes

Fingerprint

Vigabatrin
Visual Fields
Visual Field Tests
Constriction
Electroretinography
Visual Evoked Potentials
Outcome Assessment (Health Care)
Electrooculography
Ependymoglial Cells
Anticonvulsants
Visual Acuity
Retina

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Danesvar, H., Racette, L., Coupland, S. G., Kertes, P. J., Guberman, A., & Zackon, D. (1999). Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology, 106(9), 1792-1798.

Symptomatic and asymptomatic visual loss in patients taking vigabatrin. / Danesvar, Hossein; Racette, Lyne; Coupland, Stuart G.; Kertes, Peter J.; Guberman, Alan; Zackon, David.

In: Ophthalmology, Vol. 106, No. 9, 01.09.1999, p. 1792-1798.

Research output: Contribution to journalArticle

Danesvar, H, Racette, L, Coupland, SG, Kertes, PJ, Guberman, A & Zackon, D 1999, 'Symptomatic and asymptomatic visual loss in patients taking vigabatrin', Ophthalmology, vol. 106, no. 9, pp. 1792-1798.
Danesvar H, Racette L, Coupland SG, Kertes PJ, Guberman A, Zackon D. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology. 1999 Sep 1;106(9):1792-1798.
Danesvar, Hossein ; Racette, Lyne ; Coupland, Stuart G. ; Kertes, Peter J. ; Guberman, Alan ; Zackon, David. / Symptomatic and asymptomatic visual loss in patients taking vigabatrin. In: Ophthalmology. 1999 ; Vol. 106, No. 9. pp. 1792-1798.
@article{fce7de5abdf14b10af4a87e858c5ac33,
title = "Symptomatic and asymptomatic visual loss in patients taking vigabatrin",
abstract = "Purpose: To investigate the clinical, perimetric, and electrophysiologic findings in patients with visual field loss on long-term treatment with the antiepileptic medication vigabatrin. Design: Consecutive observational case series. Participants: Forty-one consecutive subjects taking vigabatrin referred for screening ophthalmologic assessment were studied. Twelve subjects with evidence of peripheral visual field constriction are presented. Methods: Twelve subjects with evidence of peripheral visual field constriction on 60-4 perimetry underwent central 30-2 and blue-on-yellow (B/Y) perimetry, as well as electroretinography (ERG), electro-oculography (EOG), and visual-evoked potential (VEP) testing. Main Outcome Measures: Visual acuity; fundus abnormalities; visual field loss; and ERG, EOG, or VEP abnormalities were the main outcome measures. Results: Eight of the 12 subjects with constricted visual fields were asymptomatic. The central 30-2 perimetry demonstrated bilateral visual field constriction in 9 of 12 patients and the B/Y perimetry in 8 of 9 patients tested. Of the ten patients tested electrophysiologically, four had abnormal ERGs, five had abnormal EOGs, and three had delayed VEPs. Conclusions: The incidence of visual field constriction in patients taking vigabatrin may be higher, and asymptomatic visual field loss more common, than reported previously. The authors postulate a possible Muller cell dysfunction in the peripheral retina. Patients taking vigabatrin should have regular peripheral visual field examinations.",
author = "Hossein Danesvar and Lyne Racette and Coupland, {Stuart G.} and Kertes, {Peter J.} and Alan Guberman and David Zackon",
year = "1999",
month = "9",
day = "1",
language = "English (US)",
volume = "106",
pages = "1792--1798",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Symptomatic and asymptomatic visual loss in patients taking vigabatrin

AU - Danesvar, Hossein

AU - Racette, Lyne

AU - Coupland, Stuart G.

AU - Kertes, Peter J.

AU - Guberman, Alan

AU - Zackon, David

PY - 1999/9/1

Y1 - 1999/9/1

N2 - Purpose: To investigate the clinical, perimetric, and electrophysiologic findings in patients with visual field loss on long-term treatment with the antiepileptic medication vigabatrin. Design: Consecutive observational case series. Participants: Forty-one consecutive subjects taking vigabatrin referred for screening ophthalmologic assessment were studied. Twelve subjects with evidence of peripheral visual field constriction are presented. Methods: Twelve subjects with evidence of peripheral visual field constriction on 60-4 perimetry underwent central 30-2 and blue-on-yellow (B/Y) perimetry, as well as electroretinography (ERG), electro-oculography (EOG), and visual-evoked potential (VEP) testing. Main Outcome Measures: Visual acuity; fundus abnormalities; visual field loss; and ERG, EOG, or VEP abnormalities were the main outcome measures. Results: Eight of the 12 subjects with constricted visual fields were asymptomatic. The central 30-2 perimetry demonstrated bilateral visual field constriction in 9 of 12 patients and the B/Y perimetry in 8 of 9 patients tested. Of the ten patients tested electrophysiologically, four had abnormal ERGs, five had abnormal EOGs, and three had delayed VEPs. Conclusions: The incidence of visual field constriction in patients taking vigabatrin may be higher, and asymptomatic visual field loss more common, than reported previously. The authors postulate a possible Muller cell dysfunction in the peripheral retina. Patients taking vigabatrin should have regular peripheral visual field examinations.

AB - Purpose: To investigate the clinical, perimetric, and electrophysiologic findings in patients with visual field loss on long-term treatment with the antiepileptic medication vigabatrin. Design: Consecutive observational case series. Participants: Forty-one consecutive subjects taking vigabatrin referred for screening ophthalmologic assessment were studied. Twelve subjects with evidence of peripheral visual field constriction are presented. Methods: Twelve subjects with evidence of peripheral visual field constriction on 60-4 perimetry underwent central 30-2 and blue-on-yellow (B/Y) perimetry, as well as electroretinography (ERG), electro-oculography (EOG), and visual-evoked potential (VEP) testing. Main Outcome Measures: Visual acuity; fundus abnormalities; visual field loss; and ERG, EOG, or VEP abnormalities were the main outcome measures. Results: Eight of the 12 subjects with constricted visual fields were asymptomatic. The central 30-2 perimetry demonstrated bilateral visual field constriction in 9 of 12 patients and the B/Y perimetry in 8 of 9 patients tested. Of the ten patients tested electrophysiologically, four had abnormal ERGs, five had abnormal EOGs, and three had delayed VEPs. Conclusions: The incidence of visual field constriction in patients taking vigabatrin may be higher, and asymptomatic visual field loss more common, than reported previously. The authors postulate a possible Muller cell dysfunction in the peripheral retina. Patients taking vigabatrin should have regular peripheral visual field examinations.

UR - http://www.scopus.com/inward/record.url?scp=0033505364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033505364&partnerID=8YFLogxK

M3 - Article

C2 - 10485552

AN - SCOPUS:0033505364

VL - 106

SP - 1792

EP - 1798

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 9

ER -